TOPFUND WHERE YOUR MONEY GROWS
Home / Stocks / Wanbury Limited
WANBURY

Wanbury Limited Share Price

Live price, chart and which mutual funds hold this stock

TopFund Score: 34/100 · Weak See breakdown ↓
…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 25 Sep 2026

₹224.15

Change

-1.0 (-0.44%)

Open

₹226.45

Prev. Close

₹225.15

Day High

₹234.25

Day Low

₹222.85

Volume Analysis

Traded

119,977

Delivered

54,928

Delivery %

45.78%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (2)

  • •Strong return on equity (76.5%)
  • •Promoter holding is rising

Weaknesses (2)

  • •High debt-to-equity ratio (3.03)
  • •Below-average fundamentals quality score (34/100)

Opportunities (1)

  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹242.71 ₹238.48 ₹231.31 ₹227.08 ₹219.91 ₹215.68 ₹208.51
Fibonacci ₹238.48 ₹234.13 ₹231.43 ₹227.08 ₹222.73 ₹220.03 ₹215.68
Camarilla ₹227.29 ₹226.24 ₹225.2 ₹227.08 ₹223.11 ₹222.06 ₹221.02

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-2.51%

1 Week

-1.49%

1 Month

-12.95%

3 Months

-20.19%

6 Months

-2.72%

1 Year

-9.09%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

DuPont ROE Breakdown

-23.49%

Net margin 6.83% × asset turnover 1.63x × equity multiplier -2.11x

Company Overview

Sector

Healthcare

Market Cap

₹784 Cr

P/E (TTM)

18.2

ROE

76.5%

Book Value

₹18.1

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 27 Sep 2026. Not investment advice.

TopFund Analysis

Wanbury Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 34/100. The strongest factor is Corporate Governance (66/100), while Financial Strength (0/100) is the weakest area to weigh before deciding. Notably: Strong return on equity (76.5%); promoter holding is rising; high debt-to-equity ratio (3.03); below-average fundamentals quality score (34/100). FII holding has been rising.

TopFund Score — Fundamentals Quality

34/100 — Weak

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 27 Sep 2026 · How we calculate this →

Financial Strength

0

Growth

20

Valuation

25

Cash Flow

38

Corporate Governance

66

Momentum

31

Institutional Ownership

40

Business Quality

58

Risk & Volatility

35

Liquidity

31

From Screener.in

  • +Company has delivered good profit growth of 30.9% CAGR over last 5 years
  • −Stock is trading at 12.4 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of 10.3% over past five years.
  • −Tax rate seems low

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 25 Sep 25 Sep
Announcement under Regulation 30 (LODR)-Change in Management 24 Sep

AGM approved cost auditor appointment for FY2026-27 and reappointed Mohan Kumar Rayana as Whole-time Director until August 2031.

Shareholder Meeting / Postal Ballot-Outcome of AGM 24 Sep 24 Sep
Announcement under Regulation 30 (LODR)-Newspaper Publication 02 Sep

Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.

Notice Of Book Closure For The Purpose Of 38Th Annual General Meeting (AGM). 31 Aug

38th AGM on 24 September 2026; book closure from 18 to 24 September 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Sales + 117 124 126 133 146 144 146 139 131 161 133 172 163
Expenses + 120 118 119 119 133 127 124 121 120 141 120 142 139
Operating Profit -3 6 6 14 13 17 21 18 11 20 14 30 24
OPM % -2.6% 4.5% 5.0% 11.0% 9.0% 12.0% 15.0% 13.0% 8.0% 12.0% 10.0% 17.0% 15.0%
Other Income + 2 1 0 -3 1 1 1 26 1 2 1 2 0
Interest 3 4 7 8 6 8 8 7 8 10 10 9 8
Depreciation 3 3 3 3 3 3 3 3 3 3 3 3 4
Profit before tax -7 -1 -3 1 5 7 10 34 1 8 1 19 14
Tax % -3.0% 25.0% 8.0% -11.0% 6.0% -2.0% 0.0% 1.0% 0.0% 2.0% 5.0% -6.0% 1.0%
Net Profit + -7 -1 -3 1 5 7 10 34 1 8 1 20 13
EPS in Rs -2 0 -1 0 1 2 3 10 0 2 0 6 4
Raw PDF — — — — — — — — — — — — —

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Sep 2014 18m Mar 2015 6m Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Sales + 661 250 420 432 370 391 367 392 511 485 557 600 630
Expenses + 637 228 387 414 438 375 344 374 475 459 484 520 542
Operating Profit 25 21 33 19 -68 16 23 18 36 26 73 80 88
OPM % 3.7% 9.0% 8.0% 4.3% -18.0% 4.1% 6.0% 4.7% 7.0% 5.0% 13.0% 13.0% 14.0%
Other Income + -78 6 0 90 76 9 84 2 77 -3 26 0 5
Interest 48 19 32 36 31 40 33 23 21 21 29 37 37
Depreciation 23 5 9 10 10 10 10 10 11 12 13 13 14
Profit before tax -125 4 -7 62 -32 -25 65 -12 81 -10 56 30 42
Tax % 2.0% 28.0% 0.0% 1.0% -1.0% -1.0% 0.0% 2.0% 0.0% 1.0% 1.0% -3.0% —
Net Profit + -128 3 -7 62 -32 -25 64 -13 81 -10 56 31 43
EPS in Rs -64 2 -4 27 -13 -10 26 -5 25 -3 17 9 13
Dividend Payout % 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% —

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Reserves -212 -214 -209 -176 -208 -233 -168 -181 -56 -66 -5 26
Borrowings + 389 381 362 300 250 260 190 192 100 95 116 179
Other Liabilities + 209 209 215 265 207 236 232 253 276 241 199 176
Total Liabilities 406 396 388 412 273 286 279 289 353 304 343 414
Fixed Assets + 174 164 180 186 178 172 164 167 167 167 167 201
CWIP 13 19 14 10 10 9 14 11 2 2 3 5
Investments 0 0 0 0 0 0 0 0 0 0 0 0
Other Assets + 219 213 193 216 84 105 101 111 183 135 174 208
Total Assets 406 396 388 412 273 286 279 289 353 304 343 414
Equity Capital 20 20 20 23 24 24 25 25 33 33 33 33

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Sep 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Cash from Operating Activity + 68 40 43 43 32 30 44 17 41 20 4 26
Cash from Investing Activity + -6 -5 -20 -13 -1 -3 64 8 1 -9 -17 -51
Cash from Financing Activity + -71 -30 -28 -27 -33 -27 -108 -17 -29 -32 15 26
Net Cash Flow -9 5 -5 3 -2 0 0 7 13 -21 2 1
CFO/OP 278 188 129 234 -49 188 188 97 113 76 6 33
Free Cash Flow 56 35 22 29 30 25 36 12 42 7 -10 -23

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 39.8% → 43.01%
  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Public 60.19% 60.2% 60.02% 59.97% 59.21% 59.4% 58.68% 58.79% 56.08% 56.21% 56.39% 56.04%
Promoters 39.8% 39.79% 39.79% 39.79% 39.77% 39.76% 39.76% 39.63% 43.09% 43.08% 43.01% 43.01%
FII 0.0% 0.0% 0.18% 0.22% 1.02% 0.84% 1.55% 1.59% 0.82% 0.72% 0.59% 0.89%
DII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.06%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Wanbury Limited (this stock) 784 18.2 12.38 76.5%
Kilitch Drugs India Ltd 786 26.2 2.81 10.6%
Gaudium Ivf N Women H L 837 36.2 5.55 24.7%
Bafna Pharmaceuticals Ltd 842 — 1.65 -6.18%
Zim Laboratories Limited 716 194.0 2.42 1.59%
Valiant Laboratories Ltd 678 42.4 2.19 -1.2%
Fabtech Technologies Ltd 661 13.6 1.58 12.5%

Which Mutual Funds Hold Wanbury Limited?

Frequently Asked Questions about Wanbury Limited

Community Sentiment

What are other investors saying about Wanbury Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.